Core Insights - Belite Bio, Inc. is focused on developing novel therapeutics for degenerative retinal diseases, specifically targeting Stargardt disease and geographic atrophy, which have significant unmet medical needs [1][5] Group 1: Presentations at ARVO Annual Meeting - The company will present two posters at the ARVO Annual Meeting from May 4-8, 2025, in Salt Lake City, Utah [1] - The first presentation will cover baseline characteristics of adolescent subjects in the Phase 3 DRAGON trial of Tinlarebant [2] - The second presentation will discuss pharmacokinetic and pharmacodynamic properties of Tinlarebant in adolescent Japanese patients [2] Group 2: Tinlarebant Overview - Tinlarebant is an oral therapy designed to reduce the accumulation of vitamin A-based toxins (bisretinoids) that lead to retinal diseases [3] - The drug works by modulating serum retinol binding protein 4 (RBP4) levels, thereby reducing bisretinoid formation [3] - Tinlarebant has received multiple designations, including Fast Track and Orphan Drug Designation in the U.S., and Sakigake Designation in Japan for treating STGD1 [3] Group 3: Stargardt Disease (STGD1) - STGD1 is the most common inherited macular dystrophy, leading to central vision loss due to mutations in the ABCA4 gene [4] - There are currently no FDA-approved treatments for STGD1, highlighting the need for effective therapies [4] - The disease progression is monitored through the accumulation of bisretinoids, which also affects patients with geographic atrophy [4] Group 4: Company Background - Belite Bio is a clinical-stage biopharmaceutical company dedicated to developing therapies for degenerative retinal diseases and specific metabolic diseases [5] - The lead candidate, Tinlarebant, is being evaluated in multiple Phase 3 studies, including DRAGON and PHOENIX, targeting both STGD1 and geographic atrophy [5]